| Company | Date | Position | Consensus ⓘ | Price Target ⓘ | 1-Yr Return | vs S&P 500 ⓘ |
|---|---|---|---|---|---|---|
|
BLTE
Belite Bio, Inc. ADR
|
Aug 11, 2026 | BUY |
Strong Buy
+10.2% avg upside
10 analysts
|
$266.00
54.47% Upside
|
-8.3% | · |
|
XNCR
Xencor
|
Aug 10, 2026 | BUY |
Strong Buy
+50.6% avg upside
27 analysts
|
$44.00
93.69% Upside
|
+8.2% | · |
|
HROW
Harrow Health
|
Aug 10, 2026 | BUY |
Strong Buy
+37.9% avg upside
12 analysts
|
$88.00
116.02% Upside
|
-1.7% | · |
|
KRRO
Korro Bio
|
Aug 06, 2026 | BUY |
Strong Buy
+104.6% avg upside
19 analysts
|
$22.00
63.60% Upside
|
+8.2% | · |
|
IFRX
InflaRx
|
Aug 06, 2026 | BUY |
Strong Buy
+342.4% avg upside
11 analysts
|
$6.00
200.02% Upside
|
+18.6% | · |
|
IRD
Opus Genetics
|
Aug 06, 2026 | BUY |
Strong Buy
+178.4% avg upside
25 analysts
|
$15.00
292.09% Upside
|
+0.0% | · |
|
INVA
Innoviva
|
Aug 06, 2026 | BUY |
Buy
+38.5% avg upside
12 analysts
|
$34.00
62.65% Upside
|
+0.1% | · |
|
SRZN
Surrozen
|
Aug 06, 2026 | BUY |
Buy
+47.3% avg upside
7 analysts
|
$40.00
63.68% Upside
|
+9.1% | · |
|
ALGS
Aligos Therapeutics
|
Aug 06, 2026 | BUY |
Strong Buy
+579.5% avg upside
11 analysts
|
$20.00
195.34% Upside
|
+22.3% | · |
|
ABCL
AbCellera Biologics
|
Aug 05, 2026 | BUY |
Strong Buy
+49.5% avg upside
15 analysts
|
$12.00
10.65% Upside
|
+87.0% | · |
|
EYPT
EyePoint Pharmaceuticals
|
Aug 05, 2026 | BUY |
Strong Buy
+151.2% avg upside
20 analysts
|
$55.00
308.41% Upside
|
+20.4% | · |
|
VKTX
Viking Therapeutics
|
Jul 29, 2026 | BUY |
Strong Buy
+117.8% avg upside
31 analysts
|
$100.00
201.90% Upside
|
-0.8% | · |
|
BCRX
BioCryst
|
Jun 30, 2026 | BUY |
Strong Buy
+84.4% avg upside
24 analysts
|
$29.00
194.33% Upside
|
-1.9% | · |
|
PHVS
Pharvaris
|
Jun 29, 2026 | BUY |
Strong Buy
+34.8% avg upside
15 analysts
|
$46.00
33.66% Upside
|
+1.2% | · |
|
SE:VICO
Vicore Pharma Holding AB
|
Jun 08, 2026 | BUY |
Strong Buy
+207.0% avg upside
2 analysts
|
$33.00
182.43% Upside
|
+12.1% | · |
|
WVE
Wave Life Sciences
|
May 18, 2026 | BUY |
Strong Buy
+302.8% avg upside
28 analysts
|
$13.00
139.79% Upside
|
-15.5% | · |
|
CAMP
CAMP4 Therapeutics Corporation
|
May 08, 2026 | BUY |
Strong Buy
+112.7% avg upside
9 analysts
|
$7.00
55.95% Upside
|
+14.3% | · |
|
PRQR
ProQR
|
Apr 14, 2026 | BUY |
Strong Buy
+509.8% avg upside
18 analysts
|
$8.00
324.45% Upside
|
-5.5% | · |
|
EQ
Equillium
|
Apr 07, 2026 | BUY |
Strong Buy
+365.2% avg upside
16 analysts
|
$10.00
370.68% Upside
|
+14.6% | · |
|
TVRD
Tvardi Therapeutics
|
Apr 01, 2026 | HOLD |
Buy
+926.8% avg upside
23 analysts
|
— | -41.0% | · |
|
JP:4593
Healios KK
|
Mar 17, 2026 | BUY |
Strong Buy
+172.4% avg upside
3 analysts
|
$1130.00
305.06% Upside
|
-41.0% | · |
|
NAMS
NewAmsterdam Pharma Company
|
Feb 19, 2026 | BUY |
Strong Buy
+77.1% avg upside
19 analysts
|
$49.00
76.53% Upside
|
-22.1% | · |
|
ALNY
Alnylam Pharma
|
Apr 28, 2025 | HOLD |
Strong Buy
+42.7% avg upside
51 analysts
|
$250.00
11.30% Upside
|
+18.5% | · |
|
QTTB
Q32 Bio
|
Dec 11, 2024 | BUY |
Buy
+290.7% avg upside
24 analysts
|
$22.00
41.68% Upside
|
-46.6% | · |
|
GILD
Gilead Sciences
|
Nov 08, 2024 | BUY |
Strong Buy
-13.7% avg upside
66 analysts
|
$103.00
25.03% Downside
|
+26.7% | · |
|
EDIT
Editas Medicine
|
Nov 04, 2024 | HOLD |
Buy
+385.5% avg upside
33 analysts
|
— | -3.5% | · |
|
ZURA
Zura Bio
|
May 10, 2024 | BUY |
Strong Buy
+180.3% avg upside
13 analysts
|
$17.00
199.24% Upside
|
-74.2% | · |
|
DNTH
Dianthus Therapeutics
|
Apr 18, 2024 | BUY |
Strong Buy
-10.6% avg upside
29 analysts
|
$51.00
53.95% Downside
|
-17.5% | · |
|
DYN
Dyne Therapeutics
|
Jan 03, 2024 | BUY |
Strong Buy
+53.5% avg upside
31 analysts
|
$56.00
113.24% Upside
|
+67.6% | · |
|
MIRM
Mirum Pharmaceuticals
|
Oct 18, 2023 | BUY |
Strong Buy
+14.6% avg upside
22 analysts
|
$77.00
22.49% Downside
|
+41.1% | · |
|
CYPH
Cypherpunk Technologies
|
Jun 23, 2023 | BUY |
Buy
+1258.0% avg upside
9 analysts
|
$17.00
2564.09% Upside
|
-49.3% | · |
|
NTLA
Intellia Therapeutics
|
May 05, 2023 | BUY |
Buy
+226.5% avg upside
37 analysts
|
$78.00
556.66% Upside
|
-46.2% | · |
|
RCKT
Rocket Pharmaceuticals
|
May 05, 2023 | BUY |
Buy
+397.3% avg upside
29 analysts
|
$35.00
947.96% Upside
|
+11.8% | · |
|
KYMR
Kymera Therapeutics
|
May 04, 2023 | BUY |
Strong Buy
-7.7% avg upside
37 analysts
|
$38.00
66.70% Downside
|
+42.5% | · |
|
MDGL
Madrigal Pharmaceuticals
|
Dec 19, 2022 | HOLD |
Strong Buy
-1.4% avg upside
33 analysts
|
— | -1.7% | · |
|
GOSS
Gossamer Bio
|
Dec 07, 2022 | BUY |
Buy
+3894.2% avg upside
17 analysts
|
$5.00
2835.13% Upside
|
-50.0% | · |
|
ANAB
AnaptysBio
|
Nov 09, 2022 | BUY |
Strong Buy
+29.2% avg upside
26 analysts
|
$38.00
33.77% Downside
|
-49.1% | · |
|
ARCT
Arcturus Therapeutics
|
Aug 10, 2022 | SELL |
Buy
+274.0% avg upside
36 analysts
|
— | -67.6% | · |
|
GLMD
Galmed Pharmaceuticals
|
May 18, 2022 | HOLD |
Buy
+4500.8% avg upside
13 analysts
|
— | · | · |
|
NEXI
NexImmune
|
Feb 22, 2022 | BUY |
Buy
+7499900.0% avg upside
4 analysts
|
$13.00
12999899.93% Upside
|
· | · |
|
GYRE
Gyre Therapeutics
|
Aug 06, 2021 | BUY |
Strong Buy
+214.9% avg upside
15 analysts
|
$18.00
169.10% Upside
|
-57.3% | · |
|
BIIB
Biogen
|
Jul 22, 2021 | HOLD |
Strong Buy
+20.6% avg upside
52 analysts
|
— | -36.8% | · |
|
CRSP
Crispr Therapeutics AG
|
Jun 13, 2021 | SELL |
Buy
+40.1% avg upside
41 analysts
|
— | +57.1% | · |
Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.